KPTI News and Press, Karyopharm Therapeutics Inc. From 02/22/22

Homology Medicines (NASDAQ:FIXX) -25% on FDA clinical hold for phenylketonuria trial. Karyopharm Therapeutics (NASDAQ:KPTI) -23% as medical chief steps down. Inspirato (NASDAQ:ISPO) -17%. QIWI (NASDAQ:QIWI) -14%. Yandex (NASDAQ:YNDX) -13%. Energy Vault (NYSE:NRGV) -12%. Ar...

Karyopharm Therapeutics (NASDAQ:KPTI) has lost ~24% in the pre-market Tuesday after the company announced that its Executive Vice President and Chief Medical Officer Jatin Shah had decided to step down to pursue other opportunities. However, Dr. Shah will continue to serve the compa...

Karyopharm Announces Changes to Its Clinical Leadership Team − Patricia Judson, M.D., Formerly of GSK and AstraZeneca, Appointed as Senior Vice President of Medical Strategy - − Stuart Poulton, Formerly of AbbVie, Amgen, and Eli Lilly, Joins as Senior Vice Pres...

Primary endpoint of phase 3 SIENDO study met in which a statistically significant improvement of progression-free survival was observed in patients treated with selinexor over placebo. NDA filing of selinexor as a maintenance therapy for patients with advanced or recurrent endometrial...

Karyopharm (KPTI +16.3%) shares surged on Friday on the news that the company had canceled its participation at the Annual SVB Leerink Global Healthcare Conference. Last week, the commercial stage biotech company announced that its Chief Executive Officer Richard Paulson would take part in a ...

Karyopharm to Participate at 11th Annual SVB Leerink Global Healthcare Conference PR Newswire NEWTON, Mass. , Feb. 11, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, t...

Karyopharm Therapeutics (NASDAQ: KPTI) outpaced many of its fellow biotech stocks on Wednesday with an almost 11% gain. This occurred after the publication of a new research note from a prominent investment bank, which found some fresh and bullish things to say about the company. ...

Gainers: Doximity (NYSE:DOCS) +20%. Aptevo Therapeutics (NASDAQ:APVO) +17%. Biofrontera (NASDAQ:BFRA) +14%. Karyopharm Therapeutics (NASDAQ:KPTI) +14%. Teva Pharmaceutical (NYSE:TEVA) +9%. Losers: Varex Imaging (NASDAQ:VREX) -11%. BioCardia (NASDAQ...

Image source: The Motley Fool. Karyopharm Therapeutics (NASDAQ: KPTI) Q4 2021 Earnings Call Feb 08, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics (KPTI) Q4 2021 Earnings Call Transcript

Karyopharm Therapeutics Inc. (KPTI) Q4 2021 Earnings Conference Call February 8, 2022 8:30 am ET Company Participants Richard Paulson - President, Chief Executive Officer Sohanya Cheng - Chief Commercial Officer Jatin Shah - Chief Medical Officer Michael Mason - Chief Financial Officer Sarah ...